Bio-Techne Corp
TECH
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.34B
Close$
$20.67
71.5% downside
Current Fair Value
71.5% downsideOvervalued by 71.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.34 Billion |
|---|---|
| Enterprise Value | $11.39 Billion |
| Dividend Yield | $0.32 (0.44%) |
| Earnings per Share | $1.17 |
| Beta | 1.3 |
| Outstanding Shares | 155,963,000 |
Return
| Return on Equity | 8.63% |
|---|---|
| Return on Assets | 7.03% |
| Return on Invested Capital | 10.06% |
Valuation & Multiples
| P/E Ratio | 61.93 |
|---|---|
| PEG | -15.15 |
| Price to Sales | 10.36 |
| Price to Book Ratio | 5.58 |
| Enterprise Value to Revenue | 9.38 |
| Enterprise Value to EBIT | 46.72 |
| Enterprise Value to Net Income | 62 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.15 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$0.52
Average shareholder expectationRevenue Estimate
$314.63 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$0.44
Average shareholder expectationRevenue Estimate
$292.61 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 9.95% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.39%▼ 113.05% |
|---|---|
| Total Invested | $44.36M▼ 99.64% |
| Investors Holding | 15▼ 600.00% |
ESG Score
No data
About Bio-Techne Corp
2,100 employees
CEO: Charles Kummeth Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's brands include flagship R&D Systems , No...